drugset / Trial / NCT00639262
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Phase 1
Completed
35 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Bayer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance radiation response. This study will test the combination of Sorafenib™ and radiation therapy with or without temozolomide to determine tolerance of the combined treatments. Defining safe dosing of Sorafenib™ in this combination therapy will be achieved.
Timeline
- Start
- 2008-03
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | — |
| Subject | Temozolomide | Small molecule | — | — |